Recent Changes

Yesterday

  1. page Expand Access to Optimized Medication-Assisted Treatment edited ... Prevent spread of infectious disease Opportunity to Enhance Common MAT Research and Practices…
    ...
    Prevent spread of infectious disease
    Opportunity to Enhance Common MAT Research and Practices
    AAn article in
    "Finally, with 6-month retention rates seldom exceeding 50% and poor outcomes following dropout, we must explore innovative strategies for enhancing retention in buprenorphine treatment."
    This report reveals the need for significantly more studies that can yield additional insights to inform MAT practices. Current literature focuses mainly on the outcome of treatment retention and negative urine drug screens. Enhanced research would look at broader outcomes of social functioning and well-being including employment, stable housing and other measures of well-being. Also, research would ideally have information on many other factors such as information on co-occurring disorders and different types of behavioral treatments that would be appropriate for different individuals, While not mentioned specifically in that article, a person's history of trauma or ACEs, length of time with an SUD, current level of supports and genetic factors such as the rates at which they metabolize different drugs would all impact what type of treatment would be most appropriate. All of these unique factors and the wide range of potential interventions are reasons that more research is needed, and conclusions from studies that look at a limited number of inputs and outcomes and lack visibility into all the unique factors that influence what might impact successful outcomes should be seen as early insights in a journey of finding the optimal forms of treatment for each person's situation.
    ...
    Induction
    "Induction is the first stage of buprenorphine treatment and involves helping patients begin the process of switching from the opioid of abuse to buprenorphine. The goal of the induction phase is to find the minimum dose of buprenorphine at which the patient discontinues or markedly diminishes use of other opioids and experiences no withdrawal symptoms, minimal or no side effects, and no craving for the drug of abuse."
    ...
    to MAT.
    Some training program suggest that Clonidine or Ondansetron may be used to ease the withdrawal symptoms during induction.
    More information on buprenorphine induction.
    ...
    http://www.samhsa.gov/medication-assisted-treatment
    https://www.whitehouse.gov/sites/whitehouse.gov/files/ondcp/commission-interim-report.pdf
    https://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.2016.16070792
    https://education.psychiatry.org/Users/ProductDetails.aspx?ActivityID=6092
    https://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2016.PP3a2
    (view changes)
    2:41 pm
  2. page Improve Access to Naltrexone Related Treatment Approaches edited ... Background Naltrexone can be used to treat opioid use disorders. It can be prescribed by any …
    ...
    Background
    Naltrexone can be used to treat opioid use disorders. It can be prescribed by any healthcare provider who is licensed to prescribe medications, special training is not required.
    Patients starting to use Naltrexone must be through a detoxification period first. This is often challenging.
    Transitioning to Naltrexone
    ...
    to injected vivetrolVivetrol (Naltrexone)
    https://www.addictionpro.com/article/medications/study-explores-challenge-initiating-patient-injectable-naltrexone
    The Bridge
    ...
    to Naltrexone.
    https://i-h-s.com/
    Tools & Resources
    (view changes)
    2:12 pm
  3. page Improve Access to Naltrexone Related Treatment Approaches edited ... Background Naltrexone can be used to treat opioid use disorders. It can be prescribed by any …
    ...
    Background
    Naltrexone can be used to treat opioid use disorders. It can be prescribed by any healthcare provider who is licensed to prescribe medications, special training is not required.
    Transitioning to Naltrexone
    New study on transitioning to injected vivetrol
    https://www.addictionpro.com/article/medications/study-explores-challenge-initiating-patient-injectable-naltrexone
    The Bridge
    The NSS-2 BRIDGE is a percutaneous nerve field stimulator (PNFS) device system, that can be used as an aid to reduce the symptoms of opioid withdrawal to help people transition to Naltrexone.
    https://i-h-s.com/

    Tools & Resources
    TR - Improve Access to Naltrexone Related Treatment Approaches
    (view changes)
    1:31 pm
  4. page TR - Enhance Support for Families of People with SUDs edited ... Description Supplemental Materials New Texting resource for parents of drug-affected [Tit…
    ...
    Description
    Supplemental Materials
    New Texting resource for parents of drug-affected
    [Title]
    Toolkit/Resource
    (view changes)
    8:40 am
  5. page Improve Access to Naltrexone Related Treatment Approaches edited ... Background Naltrexone can be used to treat opioid use disorders. It can be prescribed by any …
    ...
    Background
    Naltrexone can be used to treat opioid use disorders. It can be prescribed by any healthcare provider who is licensed to prescribe medications, special training is not required.
    New study on transitioning to injected vivetrol
    https://www.addictionpro.com/article/medications/study-explores-challenge-initiating-patient-injectable-naltrexone

    Tools & Resources
    TR - Improve Access to Naltrexone Related Treatment Approaches
    (view changes)
    8:39 am

Monday, April 16

  1. page Increase Opportunities for People to be Prescribed Buprenorphine edited ... said he has had to move his practice twice owing to complaints from the surrounding community …
    ...
    said he has had to move his practice twice owing to complaints from the surrounding community or other professional tenants in an office building about the appearance of people with addictive disorders at the practice.
    Overcoming the Barriers to Prescribing Buprenorphine
    ...
    different situations. A successful strategy should work to proactively overcome all the above barriers. Potential ways
    Additional Training on Implementing Buprenorphine and MAT
    Access to Telemedicine for Supporting Mental Health Specialists
    (view changes)
    9:14 am

Sunday, April 15

  1. page Expand DNA Testing to Improve Precision MAT Therapies edited ... In the past, physicians have had limited tools when it comes to evaluating options or dosages …
    ...
    In the past, physicians have had limited tools when it comes to evaluating options or dosages for Medication Assisted Treatment Plans
    The result is that Medication Assisted Treatment plans usually rely on a series of "trial and error" doses that are adjusted based on response of the patient to the doses being tried without using insights from genetic tests to optimize the plan for each patient.
    When ineffective MAT occurs,the does of medication is not ideal, the patient either receives noinsufficient benefit from
    ...
    impact of medication used in MAT is
    ...
    about 50%
    Patients who abstain from opioids in the first two weeks have a good chance of good 12-week outcome. However, those who use opioids in each of the first 2 weeks (even in week 1 alone) have very little chance of abstaining by week 12

    The Opportunity with Precision MAT
    With today's more refined analysis of the human genome map, their is a growing database of variability of gene alleles and how they account for changes in drug metabolism.
    ...
    https://www.naabt.org/documents/TIP40.pdf
    https://www.statnews.com/2017/11/14/vivitrol-suboxone-study-nida/
    https://education.psychiatry.org/Users/ProductDetails.aspx?ActivityID=6092
    This statistic is based on on a study of 175 people. The results are still being written up for publication.
    https://dnacenter.com/blog/swabs-vs-blood-samples-dna-testing
    (view changes)
    8:21 pm
  2. page Expand DNA Testing to Improve Precision MAT Therapies edited ... https://www.practicalpainmanagement.com/treatments/genetic-testing-pain-medicine-future-coming…
    ...
    https://www.practicalpainmanagement.com/treatments/genetic-testing-pain-medicine-future-coming
    https://www.naabt.org/documents/TIP40.pdf
    https://drugabuse.com/library/opiate-relapse/https://www.statnews.com/2017/11/14/vivitrol-suboxone-study-nida/
    This statistic is based on on a study of 175 people. The results are still being written up for publication.
    https://dnacenter.com/blog/swabs-vs-blood-samples-dna-testing
    (view changes)
    7:34 pm
  3. page Expand DNA Testing to Improve Precision MAT Therapies edited ... The result is that Medication Assisted Treatment plans usually rely on a series of "trial…
    ...
    The result is that Medication Assisted Treatment plans usually rely on a series of "trial and error" doses that are adjusted based on response of the patient to the doses being tried without using insights from genetic tests to optimize the plan for each patient.
    When ineffective MAT occurs, the patient either receives no benefit from the medication or has side effects or adverse drug reactions. See Addictive Behaviors Reports, June 2017
    ...
    relapse rate is over 75% nationallytends to be about 50%
    The Opportunity with Precision MAT
    With today's more refined analysis of the human genome map, their is a growing database of variability of gene alleles and how they account for changes in drug metabolism.
    (view changes)
    7:33 pm
  4. page Expand DNA Testing to Improve Precision MAT Therapies edited ... Genetic testing reveals information that can help us accurately tailor medications on a patien…
    ...
    Genetic testing reveals information that can help us accurately tailor medications on a patient-to-patient basis. This is called Precision or Personalized Medicine
    In the past, physicians have had limited tools when it comes to evaluating options or dosages for Medication Assisted Treatment Plans
    ...
    Treatment plans have been "hit or miss"usually rely on a series of "trial and error" doses that are largelyadjusted based on "recommended" dosing fromresponse of the FDA orpatient to the pharmaceutical industrydoses being tried without the abilityusing insights from genetic tests to optimize
    When ineffective MAT occurs, the patient either receives no benefit from the medication or has side effects or adverse drug reactions. See Addictive Behaviors Reports, June 2017
    The inconsistent impact of MAT is a contributing factor to the high relapse rates in opioid addicted patients. Even for those receiving MAT, the relapse rate is over 75% nationally
    ...
    Hamburg MA, Collins FS. The path to personalized medicine. N. Engl. J. Med. 2010;363(4):301–304.
    https://www.practicalpainmanagement.com/treatments/genetic-testing-pain-medicine-future-coming
    https://www.naabt.org/documents/TIP40.pdf
    https://drugabuse.com/library/opiate-relapse/
    This statistic is based on on a study of 175 people. The results are still being written up for publication.
    (view changes)
    6:34 pm

More